Clinical Trials Logo

Biliary Tract Neoplasms clinical trials

View clinical trials related to Biliary Tract Neoplasms.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06362317 Recruiting - Clinical trials for Biliary Tract Neoplasms Immunotherapy

Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Start date: March 6, 2024
Phase: Phase 2
Study type: Interventional

Explore the impact of the first-line application of Toripalimab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers

NCT ID: NCT06349044 Recruiting - Colorectal Cancer Clinical Trials

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Start date: March 20, 2024
Phase: N/A
Study type: Interventional

Based on the interaction between radiation therapy and immunotherapy and the potential potentiation of Probio-M9 for the treatment of ICIs, this study is planned to design an integrated treatment protocol for the first-line treatment of advanced gastrointestinal tumors through the use of macrofractionated radiotherapy as a means of immune activation, combined with the synergistic effect of Probio-M9 microbial agents and PD-1 inhibitors.

NCT ID: NCT06320301 Recruiting - Clinical trials for Biliary Tract Cancer

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

Patients with advanced biliary tract malignant tumors who had not received systematic treatment before and could not be cured were selected as the subjects of the study. The primary endpoint of the study was investigator-assessed 6-month progression-free survival (6-month PFS%) based on the RECIST v1.1 criteria, and 43 subjects were planned to be enrolled. Patients eligible for enrollment will receive Adebrelimab and a tyrosine kinase inhibitor (TKI) in combination with gemcitabine and oxaliplatin (GEMOX).

NCT ID: NCT06293898 Recruiting - Ovarian Cancer Clinical Trials

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Start date: February 9, 2024
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

NCT ID: NCT06282575 Recruiting - Clinical trials for Biliary Tract Cancer

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Start date: April 30, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.

NCT ID: NCT06282120 Recruiting - Clinical trials for Metastatic Biliary Tract Cancer

Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

Start date: January 1, 2024
Phase:
Study type: Observational

The goal of this clinical trial is to test in biliary tract cancer patients . The main questions it aims to answer are: - To evaluate the efficacy of irinotecan liposome injection combined with 5-FU/LV± immunotherapy for first-line gemsitabine + immunoprogressive metastatic biliary tract cancer - To evaluate the safety of irinotecan liposome injection combined with 5-FU/LV± immunotherapy for first-line gemsitabine + immunoprogressive metastatic biliary tract cancer This study intends to use liposomal irinotecan combined with 5-FU/LV± immunotherapy for second-line treatment of advanced biliary tract cancer that has progressed after gemsitabine + immunotherapy to evaluate the efficacy and safety of this regimen, with a view to providing better treatment options for second-line patients with advanced biliary tract cancer.

NCT ID: NCT06280508 Recruiting - Clinical trials for Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.

NCT ID: NCT06230471 Recruiting - Clinical trials for Biliary Tract Neoplasms Immunotherapy

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Start date: January 9, 2024
Phase: Phase 2
Study type: Interventional

Explore the impact of the first-line application of Pembrolizumab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers

NCT ID: NCT06202131 Recruiting - Colon Cancer Clinical Trials

Prospective Single-center Study About the Use of ctDNA in the Management of Patients With Tumors of the Gastrointestinal Tract

ctDNA-GI
Start date: November 1, 2023
Phase:
Study type: Observational

This study will evaluate the use of ctDNA in the clinical management of patients with tumors of the gastrointestinal tract.

NCT ID: NCT06139042 Recruiting - Pancreatic Cancer Clinical Trials

Early-stage Detection of LIver, Biliary tRAct and pancReatic Cancers

Start date: November 1, 2023
Phase:
Study type: Observational

LIBRARY is a prospective, multi-center, observational study aimed at detecting early liver, biliary tract, and pancreatic cancers by combining assays of cell-free DNA (cfDNA) methylation, serum protein, and microRNA.